Glaucoma 360

LL-BMT1 is a sustained drug delivery approach via a 3D-printed, drug-eluting contact lens to be used in glaucoma care that successfully completed a Phase 2b clinical trial.

At Glaucoma 360 2025, Danica Marrelli, OD, FAAO, dove into the data on visual field testing for patients with glaucoma.

Oluwatosin U Smith, MD, urges consideration of the interaction between corneal and glaucomatous disease whenever treating glaucoma or corneal issues during the annual Glaucoma 360 meeting in San Francisco, California.

A new treatment option may be on the horizon for glaucoma patients.

Optometry Times chats with Michael Chaglasian, OD, FAAO during this year's Glaucoma 360 meeting in San Francisco, California.

Robert L Stamper, MD, raises the question of physician liability for allowing the patient to drive.

Shan C. Lin, MD, discusses combined minimally invasive glaucoma surgery and its impact on achieving improved intraocular pressure efficacy.

Danica Marrelli, OD, FAAO, shares key highlights from her presentation, which she presented during the Glaucoma 360 meeting held this year in San Francisco.

According to the Ocular Hypertension Treatment Study, 5 risk factors are associated with high or low risk for primary open-angle glaucoma (POAG), with the intraocular pressure (IOP) historically being the “gold standard” and only modifiable risk factor.

Kristen Ingenito, MBA, gives key takeaways from her G360 presentation, "A bird’s eye view of innovation."

Shan Lin, MD, gives key takeaways from his G360 presentation, "The latest in IOLs: When and how to use them?"

Robert Stamper, MD, gives key takeaways from his G360 presentation, "Home tonometry: Worth the pressure?"

SpyGlass Pharma presented new data at the Glaucoma 360 New Horizons Forum that supports the use of their proprietary drug delivery platform to lower IOP in patients with glaucoma or ocular hypertension.

Sustained-release injectables may be key to addressing the greatest obstacles in glaucoma.

Oluwatosin Smith, MD, reviews different applications of minimally invasive glaucoma surgeries (MIGS) to find the best option, with the best outcome, for every patient.

Risk factors take priority

The future is sustained-release injectables

Andrew G. Iwach, MD, shares a few key highlights from his presentation regarding trend challenges of glaucoma.

Industry keenly focused on innovations

Ranya Habash, MD, shares a sneek peek of her New Horizions keynote speech on "The future of eye care: science fiction to science fact," during the 2022 Glaucoma 360 meeting.

Glaucoma 360's co-founders and co-chairs Andrew G. Iwach, MD, and Adrienne L. Graves, PhD, offer a sneak peek on what attendees can expect from this year's annual meeting.